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Introduction
Cervical cancer is the most common malignancy in women 
in Malawi, accounting for over 40% of  female cancers; it 
is a major cause of  mortality and morbidity.1–3 Accurate 
estimation of  the numbers of  women affected is complicated 
by the fact that many cancers may go unrecorded and that 
there is a lack of  a national system of  death certification. 
Two agencies, the Malawi Cancer Registry (MCR) and the 
International Agency for Research on Cancer’s (IARC) 
GLOBOCAN programme, have made recent estimates 
which differ considerably.1,3 The MCR estimated the burden 
of  new cases as 1236/year in 2009 and IARC 3684 cases/
year (2012 data). The IARC GLOBOCAN figures show that, 
at 75.9/100,000, the country currently has the highest age-
standardised incidence rate of  cervical cancer in the world.3 
Mortality, at 49.8/100,000, is also the highest recorded 
internationally and one Malawian study suggests 5-year 
survival is only 2.9%,2 lower than reports from Uganda 
and Zimbabwe, where 5-year survival is 17.7% and 26.5%, 
respectively.4,5 Survival rates achieved in high-resource 
settings are considerably higher; cancer.net reports a 68% 
5-year survival for all women with cervical cancer in the 
USA.6
The reasons for poor cancer survival in Africa are widely 
reported.7–10 There are not effective screening programmes, 
community and healthcare worker cancer awareness is poor, 
plus there is shortage of  trained professionals, oncology 
staff, treatment facilities and equipment. All these factors 
contribute to late presentation and diagnosis of  advanced 
cervical cancer is common. A range of  delays, often 
attributed to patient/community and healthcare determined 
delays have been reported, and the role of  traditional healers 
is also cited.7
Cervical cancer is an AIDS defining condition, and as 
Malawi has one of  the highest HIV prevalence rates in the 
world with 10.6% of  the adult population (15-64 years) 
having HIV (12.8% women vs 8.2% in men)2 it remains an 
important risk factor. Other prominent risk factors include 
human papillomavirus (HPV) infection, smoking and early 
age of  first sexual intercourse.
Malawians typically access conventional healthcare initially 
at local clinics and cervical screening using visual inspection 
with acetic acid is increasingly available through the National 
Cervical Cancer Control Programme.2 From clinics, patients 
can be referred to District Hospitals and to one of  three 
Central Hospitals. One of  Malawi’s two oncology units is 
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Background
Malawi has the highest age standardised rate of  cervical cancer in the world.  This study describes the presentation, management and 
short-term outcomes of  patients with newly diagnosed cervical cancer at Queen Elizabeth Central Hospital  (QECH), in Southern 
Malawi.
Methods
All patients with a new diagnosis of  cervical cancer presenting to QECH between 1st January-1st July 2015 had demographic data, 
referral pathway, stage, histology and management prospectively recorded at presentation, and at two months after initial presentation.
Results
310 women presented with cervical cancer to QECH and 300 were included (mean age 44.9 years; HIV 47%), representing 8% of  the 
estimated annual number  of  new presentations in Malawi. Mean age of  patients with HIV was 6.9 years younger compared to those 
without HIV (p<0.05). 132 (44%) patients had stage 1 cervical cancer and 168 (56%) presented with more advanced disease (stage II-IV). 
There was a mean delay of  23.1 weeks between onset of  symptoms and being seen by a clinician and a further 19 weeks before attending 
QECH.  Most common management plans at initial consultation were: same day biopsy (n=112, 37.3%);, booking for curative surgery 
(n=76, 25.3%);, and referral to palliative care (n=93, 31%). At 2 months, 64 (57%) biopsies were reported, 31 (40.8%) operations were 
completed and 27 (29%) patients had attended the palliative clinic.
Conclusions
Patients presenting with cervical cancer to QECH were young, with a high prevalence of  HIV, and late stage disease. The lack of  
pathological and surgical capacity and the absence of  radiotherapy severely limited the possibility of  curative treatment. Access to quality 
palliative care remains an important component of  management in low resource settings. Improving awareness of  cervical cancer in the 
community, and better recognition and management within the health service, are important in reducing the cancer burden for women 
in Malawi.
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based at QECH. This is the tertiary referral centre for the 
Southern region where 45% of  Malawi’s population live. 
Simple extrapolation from GLOBOCAN estimates of   3684 
incident cases of  cervical cancer in Malawi each year, suggest 
that 1658 cases should therefore be presenting to QECH 
each year (829 in 6 months).3
At QECH, women with suspected cervical cancer 
predominantly present to, and are managed, by gynaecology 
or oncology departments. The Recent American Society 
of  Clinical Oncology resource stratified guidelines would 
categorise Malawi’s treatment capacity as ‘basic’.8 The main 
treatment options in Malawi are surgery, chemotherapy and 
referral to the palliative care service at Tiyanjane Clinic based 
within QECH.9,10 Radiotherapy, not yet available in Malawi, 
is an important treatment option in cervical cancer and 
potentially 60% to 70% of  patients would benefit from it 
with possible cured.11 A small number of  patients do access 
radiotherapy in other countries either self-funded or through 
a Malawi Government scheme.
Within QECH concerted efforts are being made to implement 
multidisciplinary cancer care.12 As inpatient care becomes 
more standardised the potential for systematic data collection 
about patients, cancer type and stage is developing. However 
much about the patient pathway before and after hospital 
remains unclear. Understanding the clinical epidemiology of  
cervical cancer and patient management pathways is crucial 
to improving care. We therefore undertook an analysis of  6 
months of  cervical cancer presentations to QECH.
Methods
All patients presenting to gynaecology and oncology 
departments between 1st January and 1st July 2015 
(outpatient or inpatient services) with a new clinical and/or 
histologically confirmed diagnosis of  cervical cancer were 
included. New cases of  suspected cervical cancer in other 
departments within the hospital are referred to gynaecology 
or oncology, therefore to ensure capture of  all new cases in 
QECH patients were identified by daily search of  inpatient 
admission books in Gynaecology and Oncology wards and 
identification in respective new patient clinics. Patients who 
did not provide informed consent or those with a previous 
diagnosis of  cancer were excluded.
Patients were clinically assessed at first presentation by a 
research clinician (registrar or consultant) who, after gaining 
consent, completed a standard study proforma. Patient 
demographics, presenting symptoms, time and pathway to 
presentation, risk factors, stage of  disease at presentation, 
initial investigation and treatment were recorded. Cervical 
Table 1: Stage and mean age of all women enrolled in the study, divided into those with HIV, without 
HIV, and in those in which HIV status was unknown
Stage
All patients Patients with HIV
Patients without 
HIV
Patients with 
unknown HIV status
Number Mean age Number Mean age Number Mean age Number Mean age
I 132 42.1 63 39.4 59 44.4 10 45.0
II 79 45.7 41 41.5 34 49.6 4 55.5
III 69 47.8 29 42.2 34 51.5 6 54.3
IV 20 50.4 8 45.9 9 49.1 3 66.0
All 300 44.9 141 40.9 136 47.8 23 52.0
Table 1: Stage and mean age of all women enrolled in the study, divided into those with HIV, without HIV, and in those 
in which HIV status was unknown
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Figure 1: CONSORT diagram illustrating the number of patients with cervical cancer included in the 
study
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presentations in Malawi.3 Two patients did not consent, one 
was unable to consent, and seven patients with a positive 
visual inspection by acetic acid (VIA) were excluded from 
the analysis as they were not staged. Considering 45% of  the 
population live in the Southern Region, we estimate these 
300 patients represent 36% of  the expected cases in this 
region over this time period.
Mean age of  patients was 44.9 years (range 19-86 years) 
and this increased with stage of  disease. 141 (47%) patients 
had HIV, 136 (45.3%) patients did not have HIV, and 23 
(7.6%) did not know their HIV status (Table 1). Mean age of  
patients with HIV was 6.9 years younger than those without 
HIV (P < 0.01, 95% confidence interval 3.9 to 9.9). This age 
difference was consistent across all stages of  cervical cancer. 
To facilitate analysis, we created two groups by coalescing 
stage – Early (FIGO Stage I-IIA) and Advanced (Stage IIB-
IV). 184 (61.3%) patients had early disease (mean age 42.5), 
and 116 (38.6%) patients had advanced disease (mean age 
48.7) at diagnosis (Table 2).
The patient pathway
Source of referral
Nine (3%) women presented asymptomatically through 
screening after having a VIA indicating a cancer.  Of  the 291 
patients who presented with symptoms, 169 (58%) women 
had been referred from a clinic and 122 (42%) from other 
hospitals. 
The mean delay between women recognizing symptoms 
and presenting to a clinician was 23.1 weeks with a further 
19 weeks before presentation at QECH—meaning that 
the total delay between becoming aware of  symptoms and 
cancer was staged with the revised International Federation 
of  Gynaecology and Obstetrics (FIGO) staging system for 
cervical cancer.13
In all enrolled patients, follow up data was collected at one and 
two months after initial presentation to determine whether 
they had received their treatment/management documented 
at their initial consultation. We reviewed inpatient and 
outpatient medical records in addition to histopathology 
reports from the laboratory for biopsy results, theatre lists for 
confirmation of  completed operations, attendance records at 
oncology and palliative care clinics, and attempted to phone 
all palliative care patients at 2 months for confirmation of  
outcome.
Data was anonymised at the point of  capture, recorded 
on password protected computers in password protected 
files only accessible to the study team, and analysed using 
Microsoft Excel. We compared variables between patients 
with different stages of  
cervical cancer using 
standard parametric and non-
parametric tests according to 
the distribution of  variables, 
in addition to comparing 
patients with and without 
HIV. To facilitate analysis, 
we created two groups by 
combining patients with 
FIGO stage I-IIA disease 
(surgically resectable) 
and stage IIB-IV (non-
resectable), referred to as 
early and advanced cervical 
cancer respectively. 
Ethics approval for the study 
was granted by the College 
of  Medicine Research 
Ethics Committee (reference 
P.01/15/1670).
Results
310 patients presented 
with a clinical diagnosis of  
cervical cancer between 1st 
January and 1st July 2015, 
and 300 of  these were 
included in the analysis 
(Figure 1), representing 8% 
of  the estimated total annual 
number (3684) of  new 
Table 2: Number of patients presenting with early and advanced cancer 
classified by age group
Age 
(years)
Early cancer 
(stage I to IIA)
Advanced cancer 
(stage IIB to IV)
< 30 24 2
30 to 39 62 29
40 to 49 51 35
50 to 59 26 23
60 to 69 9 20
≥ 70 12 7
Total 184 116
Table 2: er of patients prese ting with early and adva ced 
cancer classified by age group
Table 3: Mean time period (weeks) between symptom onset, first clinical assessment, and clinic 
appointment in patients with early and advanced cervical cancer at Queen Elizabeth Central Hospital
Cancer stage Number of women
Mean time 
between 
symptoms to 
first healthcare 
visit (weeks)
Mean time 
between first 
healthcare visit 
to QECH 
appointment 
(weeks)
Mean total 
time between 
symptoms to 
QECH 
appointment 
(weeks)
Early 
(stage I to IIA)
184 
(61.3%) 22.4 17.4 39.9
Advanced 
(stage IIB to IV)
116 
(38.7%) 23.9 21.4 45.3
All cases 300 23.1 18.7 42.0
Table 3: Mean time period (weeks) between symptom onset, first clinical assessment, and clinic 
appointment i  patients with arly and advanced cervical cancer at Queen Elizabeth Central 
Hos ital
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Figure 2: Time to present to hospital from symptom onset according to stage of disease
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Pathology
229 women (76%) had a biopsy taken and 126 (55%) reports 
were available. 31(25%) were reported within one month, 
72 (57%) by 2 months, the remaining 53 (42%) after this. 
Of  the 71 patients who were not biopsied, 54 (76.1%) had 
advanced disease (stage II to IV). 
91(39.7%) biopsies confirmed cervical cancer (87 Squamous 
cell carcinoma, 3 adenocarcinoma, 1 Kaposi’s sarcoma) and 
9 (3.9%) demonstrated cervical intraepithelial neoplasia. The 
remaining reports showed cervicitis (n = 14), dysplasia (n = 
5), wart (n = 1) and a nabothian cyst (n = 1). The remaining 
5 were suboptimal samples. 54 (59%) of  the 91 confirmed 
cancer cases were available 2 months or more after the date 
of  biopsy.
Palliative care
Of  93 patients referred to palliative care, 27 (29%) were seen 
locally in the Tiyanjane palliative care clinic at QECH. In 
addition we attempted to phone all palliative care patients 
at 2 months: 42 patients had no mobile phone; there was no 
answer in 23; 10 had been to palliative care and were alive; 8 
were alive and had not been to palliative care; 2 were awaiting 
chemotherapy; 5 were on chemotherapy; and 3 had died. 
Oncology
Chemotherapy was initiated within a month for 6 of  the 8 
patients where this was planned (although one subsequently 
died between 1 and 2 months). One patient had private 
radiotherapy abroad and started this between 1 and 2 months. 
2 were on no treatment, alive and well.
Discussion
Case numbers
This is a large case series of  accurately clinically staged 
cervical cancer reported from an African country. We show 
that 300 cases present to QECH in 6 months, a caseload 
consistent with Malawi Cancer Registry figures.1 The Malawi 
Cancer registry largely relies on returns from QECH for 
their data collection so it is reassuring that our findings are 
of  a similar scale. However they are considerably below 
GLOBOCAN estimates of  1658 new cases in Southern 
region, which implies that many women with cervical cancer, 
if  they receive formal healthcare, are treated in local clinics 
or hospitals and never reach QECH.3 It may be that not all 
patients are referred from community clinics, patients may 
not have the means to get there, or they may choose to 
have alternative therapies and see no need in attending the 
hospital.
Patient characteristics
As in many Low and Middle Income Countries, the spectrum 
of  presentation is skewed towards more advanced disease. 
This is complex to treat and an annual caseload of  600 cases 
is large for any hospital. It is a certainly a logistical challenge 
for QECH with its small clinical workforce and limited 
resources.8 The average age of  our patients was 42 years, 
which is younger in comparison to 46.5 years in Zimbabwe, 
and 49 years in the US.14 The reasons for this are complex 
and unknown but highlights the need for public education 
on cervical cancer screening to start in younger age groups. 
The impact of  HIV is obvious with 47% having HIV and as 
a group an average of  7 years younger than women without 
HIV. These points plus the fact that other characteristics 
regarding parity and sexually transmitted disease were 
consistent with published data gives us reassurance that we 
QECH appointment was 42 weeks. Women with advanced 
disease at presentation experienced longer delays amounting 
to a month more between symptom recognition and 
QECH appointment (Table 3). When we compared time to 
presentation with stage of  disease (I-IV), there was a trend 
of  increased time to presentation with the more advanced 
disease at diagnosis (Figure 2). 
We also compared the healthcare delay between first 
healthcare visit at a community clinic (169 women) or a 
hospital setting (122 women) to diagnosis at QECH. The 
delay was 16.3 and 21.7 weeks, respectively. There was a trend 
towards quicker referrals from a clinic. Despite these trends, 
there were no statistical differences in delays attributable to 
early/advanced stage of  disease or to source of  referral.
Initial symptoms
The commonest initial symptom reported was vaginal 
bleeding (often post coital) in 105 (35.0%) women, and 
vaginal discharge in 62 (20.5%) with dysuria (n = 7, 2.3%), 
abdominal pain (n = 3, 1.0%), vomiting and weight loss (n = 
3, 1.0%) also featuring.  
Risk factors
Median age of  first sexual intercourse was 17 (IQR 15 to 
19) and 124 women (41.3%) had their first birth under 20 
years of  age. 87 (29%) said they had more than three sexual 
partners and 45 (15%) said they had previously had a sexually 
transmitted disease. 156 (52%) patients had five or more 
children. Six (2%) patients had a family history of  cervical 
cancer, and 26 (8.7%) were smokers (Figure 3).
128 (42.6%) said they were aware of  cervical screening, 
however only 7 (2.3%) of  these patients knew the correct 
age that screening is offered in Malawi.9 (3%) said that they 
had heard of  the HPV vaccine; none of  300 patients were 
vaccinated. 100 (33.3%) patients had never had a speculum 
or VIA examination before presentation to specialist services 
at QECH.
Management
286 (95%) patients were reviewed by gynaecology and 14 
(5%) by Oncology; we recorded the management plan at 
this first clinic appointment. The commonest plan, in 112 
cases (37.3%), was to have a same day biopsy and return for 
review when results were available. In the remainder, direct 
referrals were made at that first appointment to: palliative 
care (n = 93, 31%), surgery (n = 76, 25.3%), oncology for 
chemotherapy (n = 8, 2.6%), and radiotherapy (n = 1, 0.3%). 
Ten (3.3%) patients were asked to attend QECH at a later 
date with no management plan recorded due to overbooked 
clinics. 
Short-term outcomes
Surgery
Of  the 76 operations that were planned, 31 (40.8%) were 
carried out, 8 (10.5%) within 1 month of  appointment, 10 
(13.2%) within two months of  appointment, and 13 (17%) 
after two months. The remainder (n = 45; 59.2%) were not 
carried out due factors including progression of  disease and 
cancellation of  surgery by clinician or surgical coordinator. 
Two patients were unable to attend due to no money for 
transport to the hospital. Three surgeries were delayed due 
to water shortages. Mean time from initial appointment 
to surgery was 31.8 days (range 2 to 109 days). Of  the 31 
patients with surgical findings documented, 30 were early 
surgically resectable cancers and one was advanced (Stage 
IIB). 
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have a nationally representative sample of  cervical cancer 
patients.15,16 HIV positive women in our sample were almost 
all on antiretroviral medication. This reflects the success of  
Malawi’s AIDS treatment programme within which VIA is 
promoted and whose staff  could be helpfully given training 
about detecting cancer early.16,17
Awareness of cervical cancer and screening
Improving public awareness that cervical cancer is one of  
the largest health problems for women in Malawi is crucial. 
Knowledge about the two most important preventive 
measures available, cervical screening and the HPV vaccine, 
was low in our sample of  women with cervical cancer, 
absolutely the target group for preventive messages. The 
Malawi SRHR policy for cervical cancer prevention and 
control mentions neither the vaccine nor the age at which 
screening should start.18 This information needs to be 
clearly communicated to the public. Clear referral pathways 
from community hospitals/clinics with time targets should 
be established in order to improve coordination between 
primary, secondary and tertiary services. Information for 
clinicians and women attending ARV clinic and a referral 
pathway to screening would improve awareness and screening 
rates of  asymptomatic women.
Delays in presentation
In the UK, NHS England has national guidelines for patients 
with a suspected cancer, stating that they must be seen in 
a specialist clinic within 2 weeks of  symptom onset, and 
for definitive treatment to be initiated within 62 days.19 The 
overall delay from symptoms onset to first QECH clinic 
appointment of  42 weeks in our study is long, and is likely 
to have contributed to the presentation of  advanced stage 
disease. The common causes of  delays seen elsewhere 
in presenting to healthcare with symptoms suggestive of  
cancer were identified.20 We were unable, however to detect 
any sub group of  women with particular types of  delay by 
age or source of  referral. Certainly we need to investigate 
the causes of  delayed cancer presentation in Malawi, and 
discover why these may be different if  at all to other types 
of  disease. Reviewing the existing Malawian evidence about 
uptake and adherence to cervical screening and other fields 
such as tuberculosis and AIDS and thinking how this could 
transfer to cancer care would be useful.18 The healthcare 
component in the delay (between contact with the referring 
hospital or clinic and being seen at QECH) was still almost 
19 weeks, nearly half  of  the total. We have accumulated 
examples of  substandard practice such as lack of  clinical 
assessment using a speculum at local centers and prolonged 
antibiotic use before referral. Given that a relatively small 
number of  hospitals and clinics made the referrals, some 
focused training should be possible. Clinicians uniformly 
mention the trust women place in traditional healers and 
herbalist and the large proportion of  women who received 
care from them prior to coming to the health service likely 
resulted in delay. Consequently the traditional healer cadre 
could be offered some basic training to alert them to 
suspicious symptoms and refer these women to the health 
service. With enhanced training in signs and symptoms of  
cancer, clinicians would quickly become more skilled at 
cancer detection and outcomes could improve sharply.21 
Clinicians and support staff  should also be supported to 
develop referral systems and methods of  feedback so that 
referring clinicians learn from their decisions and standards 
improve. 
Diagnosis
In resource-poor countries such as Malawi, specialists in 
diagnostic specialties such as pathology and radiology are 
particularly rare. Pathology services at QECH face significant 
challenges and under half  of  specimens taken had reports 
available two months after biopsy. While rapid initiation of  
treatment informed by pathology was often not possible, 
those patients who had surgery were treated an average of  
just over one month from first being seen – a speed that rivals 
the developed world. The women who had operations were 
overwhelmingly early stage cancers where cure is feasible 
highlighting that the correct clinical prioritization process 
took place. A high proportion of  women with advanced 
disease were referred directly to palliative services.
Treatment 
However, about half  of  operations did not take place as 
intended. While this loss to follow-up requires further 
investigation, it is highly unlikely that the surgical capacity 
to tackle this oncology workload will exist in the foreseeable 
future in Malawi. Radiotherapy offers the possibility 
of  cure for many women who currently cannot access 
potentially curative therapy. As data from the International 
Atomic Energy Authority show that radiotherapy would 
benefit some 60% of  these women, this emphasises the 
importance of  realising the National Non Communicable 
Disease strategy and bringing radiotherapy to Malawi.11,22,23 
A specialist cervical cancer nurse could be appointed to 
coordinate this group of  patients. A key responsibility would 
be coordinating a multidisciplinary team meeting between 
gynaecology, oncology and palliative care teams.
In a review of  cervical cancer research in Africa, 
Finnocchario-Kessler et al highlighted the importance of  
severely affected countries such as Malawi increasing the 
amount of  local research into cervical cancer treatment. This 
work demonstrates the large numbers of  women are coming 
forward for treatment. It illustrates the challenges they pose 
for treatment services and adds to recent large reports from 
Malawi on cervical screening and palliative care in cervical 
cancer patients.10,24 This is important in helping to complete 
the picture of  the clinical epidemiology of  the condition in 
the country.
Limitations
Whilst QECH provides the oncological service for Southern 
Malawi, we are aware our population may not represent all 
the cases of  cervical cancer in the region due, in part, to the 
logistical and financial challenges of  travelling large distances 
for tertiary care. Collecting data prospectively improves 
accuracy of  data capture as we do not have to rely on finding 
missing patient notes. The complete ascertainment of  cases 
gives a comprehensive picture of  the workload and their large 
number allows statistical analysis and confident conclusions. 
Our ambitions to collect follow up data were compromised 
by this well-recognised difficulty in resource poor settings. 
Tiyanjane Clinic in a 2015 cervical cancer palliative care case 
series experienced 33% loss to follow-up.10 Our efforts to 
contact patients by telephone to ascertain their status were 
largely unsuccessful and we are working with the MCR to 
develop more robust follow-up systems to collect outcome 
data.
Conclusions
Our results indicate that patients presenting with cervical 
cancer to QECH are young, with a high prevalence of  HIV, 
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and late stage disease. The cohort was largely unaware of  
preventive initiatives such as HPV vaccination and cervical 
screening, and awareness programmes such as the ‘Cancer 
below the belt’ campaign should be promoted. VIA is widely 
available in Malawi and should, where possible, be routinely 
performed along with a speculum exam during every 
gynaecological or pelvic examination, particularly in patients 
with HIV whom are at a much increased risk of  cervical 
cancer. The lack of  pathological and surgical capacity and 
the absence of  radiotherapy severely limits the possibility of  
curative treatment. While the Government’s plans to increase 
the number of  staff  working in cancer care are important, 
a significant advance for cervical cancer patients will come 
with the widespread use of  HPV vaccination and the arrival 
of  radiotherapy in the country.
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